LEADER 01541nam  2200421Ia 450 
001 9910698978503321
005 20090618110942.0
035   $a(CKB)5470000002398088
035   $a(OCoLC)402487747
035   $a(EXLCZ)995470000002398088
100   $a20090618d2005      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $eS7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticals
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research :$cCenter for Biologics Evaluation and Research,$d[2005]
215   $a10 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on June 19th, 2009).
300   $a"ICH".
300   $a"October 2005".
517   $aGuidance for industry 
606   $aHeart$xVentricles
606   $aPalpitation
606   $aDrugs$xTesting
615  0$aHeart$xVentricles.
615  0$aPalpitation.
615  0$aDrugs$xTesting.
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
712 12$aInternational Conference on Harmonisation.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698978503321
996   $aGuidance for industry$93434577
997   $aUNINA